SPACTORY (101189238)

  https://cordis.europa.eu/project/id/101189238

  Horizon Europe (2021-2027)

  SPACTORY, revolutionising pharmaceutical development and manufacturing through microgravity

  EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOROPEN-01)

  satellite technology  ·  proteins

  2024-08-01 Start Date (YY-MM-DD)

  2026-07-31 End Date (YY-MM-DD)

  € 0 Total Cost

  Description

Over 2,000 R&D experiments have been done in Space until now. Space near-zero gravity yields biochemical crystals orders of magnitude more defined, pure, uniform, and precise than in terrestial environments. The low-gravity accelerates the development and preclinical testing of complex molecules –e.g. proteins- and unleashes the potential of innovative high-value mAbs therapies, saving patient’s lives and improving their QoL. To make it real, after 11 space missions, SPACEPHARMA is committed to bringing the first mAbs factory to Space. MOTI, the main SPACTORY building block, brings accessible, scalable, and affordable microgravity manufacturing controlled from Earth and able to fly in any satellite compatible with any launcher. For our customers, the pharma industry, it means shorter time to Space, faster market access and affordable drug development. For SPACEPHARMA, it is a paradigm shift from drug R&D to manufacturing. For EU, it means leading the spatial race in drug development.

  Complicit Organisations

1 Israeli organisation participates in SPACTORY.